Antares Pharma Stock Forecast for 2023 - 2025 - 2030
Updated on 01/31/2023
Antares Pharma Stock Forecast and Price Target
If the average 2023 price target of $5.25 recently set by two prominent experts for Antares Pharma is met, there would be a potential downside of approximately -6.08% from the last closing price in May, 2022. The high estimate is $5.89, and the low is $4.68. If you're interested in investing in this company, why not also look at its competitors to see how they are doing?
-6.08% Downside
Antares Pharma Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Antares Pharma's Price has grown, moving from $0.00 to $1.79 – an increase of 100.00%. According to 0 analysts, Antares Pharma's Fair Value will fall by 65.56% in the next year, reaching $0.61. Professionals believe that By 2030, Antares Pharma's Fair Value will fall to $1.17 – a 34.23% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$344.15 | $333.19 | 16.23% |
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$147.74 | $162.12 | 11.68% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$44.16 | $53.97 | 19.23% |
| CVS Stock Forecast | CVS Health Corp | Outperform |
13
|
$88.23 | $115.94 | 30.96% |
| GSK Stock Forecast | GSK | Hold |
16
|
£1.42k | £16.95 | -98.87% |
Antares Pharma Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Antares Pharma's Revenue has grown, moving from $123.86M to $183.98M – an increase of 48.54%. According to 0 analysts, Antares Pharma's Revenue will fall by 18.20% in the next year, reaching $150.50M. Professionals believe that By 2030, Antares Pharma's Revenue will fall to $154.77M – a 15.88% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Outperform |
18
|
Rp1.01k | Rp845.39 | 2.61% |
| WST Stock Forecast | West Pharmaceutical Services | Outperform |
18
|
$265.60 | $402.50 | -3.99% |
| VTRS Stock Forecast | Viatris | Outperform |
8
|
$12.15 | $13.70 | 11.11% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Hold |
12
|
$10.54 | $12.04 | -5.12% |
| PRGO Stock Forecast | Perrigo | Buy |
16
|
$37.42 | $47.75 | 26.94% |
| 4183 Stock Forecast | Mitsui Chemicals | Hold |
18
|
¥2.99k | ¥0.00 | 30.65% |
Antares Pharma Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Free Cash Flow for Antares Pharma has grown by 331.30%, going from $-12.97M to $30.00M. For the following year, the 0 analysts predict that Antares Pharma's Free Cash Flow will drop by 110.95%, reaching $-3.29M. In 2030, the professionals' prediction is that NasdaqCM:ATRS's Free Cash Flow will decrease by 478.30%, reaching $-113.49M.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| YPSN Stock Forecast | Ypsomed Holding | Outperform |
18
|
CHF131.20 | CHF154.00 | 44.82% |
| ENDP Stock Forecast | Endo International | Underperform |
14
|
$0.41 | $0.00 | 143.90% |
| ALCJ Stock Forecast | Crossject Société Anonyme | Sell |
9
|
3.09€ | 1.70€ | 107.12% |
Antares Pharma Net Income Forecast for 2023 - 2025 - 2030
Antares Pharma's Net Income has seen growth In the last two years, going from $-2.03M to $46.29M – a gain of 2380.30% 0 analysts predict Antares Pharma's Net Income will decrease by 20.26% in the next year, reaching $36.91M. By 2030, professionals predict that Antares Pharma's Net Income will decrease by 16.41%, to $38.70M.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| MDP Stock Forecast | Medexus Pharmaceuticals | Outperform |
0
|
C$2.80 | C$0.00 | 96.43% |
| ASP Stock Forecast | Acerus Pharmaceuticals | - |
0
|
C$2.83 | C$0.00 | 9.19% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$72.51 | $80.99 | 14.47% |
Antares Pharma EBITDA Forecast for 2023 - 2025 - 2030
Antares Pharma's EBITDA has grown in the last two years, jumping from $3.55M to $31.24M – an increase of 780.00%. In the following year, the 0 analysts surveyed believe that Antares Pharma's EBITDA will decrease by 58.04%, reaching $13.11M. According to professionals, by 2030, Antares Pharma's EBITDA will have decreased by 35.69%, falling down to $20.09M.
Antares Pharma EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Antares Pharma's EBIT has increased by 2661.62%, going from $990.00k to $27.34M. The next year, 0 experts forecast that Antares Pharma's EBIT will decrease by 64.36%, reaching $9.74M. In 2030, professionals predict that Antares Pharma's EBIT will decrease by 34.73%, reaching $17.85M.
Antares Pharma EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Antares Pharma's EPS has grown, moving from $-0.01 to $0.10 – an increase of 1100.00%. According to 0 analysts, Antares Pharma's EPS will fall by 65.56% in the next year, reaching $0.03. Professionals believe that By 2030, Antares Pharma's EPS will fall to $0.07 – a 34.23% decrease from its current value.